Tagged with B

Saudi Arabia The top 10 pharma companies in Saudi Arabia ranked by sales value in USD millions MAT Q1 2019. These top 10 corporations account for 50 percent of total sales in the USD 8.2 billion Saudi pharma market. Global giants Pfizer, Sanofi, and Novartis make up the top three spots, but…

News Roundup The latest from the fight against COVID-19 in Latin America, including J&J’s vaccine trials, issues surrounding Chinese-made diagnostic tests, Colombia’s vaccine manufacturing capacity, and potential compulsory licensing in Brazil.   COVID-19 vaccine: J&J seeks 20,000 trial volunteers in Latin America, one-third of planned global total https://www.businesstoday.in/sectors/pharma/COVID-19-vaccine-jj-seeks-20000-trial-volunteers-in-latin-america/story/415224.html Josue Bacaltchuk, vice president…

Global Dr Muhammad Ali Pate, Global Director for Health, Nutrition and Population at the World Bank as well as Director of the Global Financing Facility for Women, Children and Adolescents, reflects on the impact of the current COVID-19 pandemic on the work that the global institution has been doing to promote…

Belgium An overview of health and healthcare in Belgium with data on the country’s leading causes of death, healthcare expenditure and hospital infrastructure.   The top 10 causes of death in Belgium; ischemic heart disease stayed at number one between 2007 and 2017. Made with Visme Infographic Maker   Current levels of…

Roundup A roundup of the latest news from pharma in the Middle East and Africa including China’s announcement that it will be prioritising Africa for access to its COVID-19 vaccine, UAE firm Mubadala’s latest US investment, Saudi Arabia’s continuing digitalisation push, and Algeria’s plan to export USD five billion in domestically…

Norway Norway, known more for its expertise in oil and gas and marine biology than in health innovation, is home to increasing numbers of innovative medical technology start-ups. Here are five of the most exciting such companies, as selected by Kathrine Myhre, founder and CEO of Oslo-based innovation cluster Norway Health…

Canada The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis clinical trial, and Innovative Medicines Canada’s top priorities.   Canada signs deals for J&J, Novavax COVID vaccines https://pharmaphorum.com/news/canada-signs-deals-for-jj-novavax-COVID-vaccines/ Under the…

Korea Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans.   We were the first Korean biotech to have independently developed, commercialized, marketed and exported an innovative drug Dr Cho, could you start by…

USA Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product XPOVIO®, his ambitious internationalisation plans, and the challenges of being a biotech entrepreneur.   From my experience, many great ideas actually come from people unconstrained by the…

China The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.   Canada scraps COVID-19 vaccine trial with Chinese CanSinoBIO https://globalnews.ca/news/7302041/canada-china-covid-19-vaccine-trials-abandoned-national-research-council/ Canada has decided to cancel a coronavirus vaccine development agreement…

China Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from the crowd in China. He also touches on commercialization, partnerships, funding, and the evolution of the Chinese biopharma landscape.  …

USA Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture.   We…